FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020267524> ?p ?o ?g. }

• W2020267524 endingPage "845" @default.
• W2020267524 startingPage "833" @default.
• W2020267524 abstract "Objective:To systematically assess efficacy and safety of buprenorphine patch versus fentanyl patch in patients with chronic moderate to severe pain.Methods:Fifteen databases were searched up to December 2010. Randomised and quasi-randomised trials assessing the efficacy in patients with chronic pain were included. Quantitative methods for data synthesis were used and two network meta-analyses were conducted.Results:Fourteen unique trials (17 publications) were included. No head-to-head randomised trials of buprenorphine patch compared with fentanyl patch were identified. Therefore, less robust evidence from indirect comparisons was used. Results from a network meta-analysis of non-enriched designs (eight trials), using trials versus placebo and trials versus morphine for indirect comparisons, indicated that transdermal fentanyl, in comparison with transdermal buprenorphine, showed significantly more nausea (odds ratio [OR] 4.66, 95% confidence interval (CI) 1.07 to 20.39), a significantly higher number of treatment discontinuations due to adverse events (OR 5.94, 95% CI 1.78 to 19.87), and non-significant differences on all other outcomes, including pain measures. In comparison with morphine, transdermal buprenorphine had a significantly higher decrease of pain intensity (MD [mean difference] −16.20, 95% CI −28.92 to −3.48) while morphine caused more cases of constipation (OR 7.50, 95% CI 1.45 to 38.85) and a significantly higher number of treatment discontinuations due to adverse events (OR 5.80, 95% CI 1.68 to 20.11). All other outcomes showed non-significant differences between transdermal buprenorphine and morphine. The results were similar when also including six trials using enriched designs with the exception of more cases of vomiting for fentanyl (OR 17.32, 95% CI 4.43 to 67.71) and morphine (OR 15.85, 95% CI 3.92 to 64.13) compared to buprenorphine.Conclusions:The findings indicate comparability of transdermal buprenorphine and transdermal fentanyl for pain measures with significantly fewer adverse events (nausea and treatment discontinuation due to adverse events) caused by transdermal buprenorphine." @default.
• W2020267524 created "2016-06-24" @default.
• W2020267524 creator A5001156294 @default.
• W2020267524 creator A5027602269 @default.
• W2020267524 creator A5068186079 @default.
• W2020267524 creator A5069841995 @default.
• W2020267524 creator A5071060308 @default.
• W2020267524 creator A5075448540 @default.
• W2020267524 creator A5080052175 @default.
• W2020267524 date "2012-04-25" @default.
• W2020267524 modified "2023-10-18" @default.
• W2020267524 title "Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain" @default.
• W2020267524 cites W1951897616 @default.
• W2020267524 cites W1970071446 @default.
• W2020267524 cites W1982422239 @default.
• W2020267524 cites W2000748607 @default.
• W2020267524 cites W2008023699 @default.
• W2020267524 cites W2017424116 @default.
• W2020267524 cites W2027440347 @default.
• W2020267524 cites W2029179831 @default.
• W2020267524 cites W2029228559 @default.
• W2020267524 cites W2038973797 @default.
• W2020267524 cites W2050341237 @default.
• W2020267524 cites W2059867560 @default.
• W2020267524 cites W2083015822 @default.
• W2020267524 cites W2095248985 @default.
• W2020267524 cites W2107328434 @default.
• W2020267524 cites W2113933207 @default.
• W2020267524 cites W2117950925 @default.
• W2020267524 cites W2128750463 @default.
• W2020267524 cites W2148000461 @default.
• W2020267524 cites W2149012794 @default.
• W2020267524 doi "https://doi.org/10.1185/03007995.2012.678938" @default.
• W2020267524 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22443154" @default.
• W2020267524 hasPublicationYear "2012" @default.
• W2020267524 type Work @default.
• W2020267524 sameAs 2020267524 @default.
• W2020267524 citedByCount "59" @default.
• W2020267524 countsByYear W20202675242012 @default.
• W2020267524 countsByYear W20202675242013 @default.
• W2020267524 countsByYear W20202675242014 @default.
• W2020267524 countsByYear W20202675242015 @default.
• W2020267524 countsByYear W20202675242016 @default.
• W2020267524 countsByYear W20202675242017 @default.
• W2020267524 countsByYear W20202675242018 @default.
• W2020267524 countsByYear W20202675242019 @default.
• W2020267524 countsByYear W20202675242020 @default.
• W2020267524 countsByYear W20202675242021 @default.
• W2020267524 countsByYear W20202675242022 @default.
• W2020267524 countsByYear W20202675242023 @default.
• W2020267524 crossrefType "journal-article" @default.
• W2020267524 hasAuthorship W2020267524A5001156294 @default.
• W2020267524 hasAuthorship W2020267524A5027602269 @default.
• W2020267524 hasAuthorship W2020267524A5068186079 @default.
• W2020267524 hasAuthorship W2020267524A5069841995 @default.
• W2020267524 hasAuthorship W2020267524A5071060308 @default.
• W2020267524 hasAuthorship W2020267524A5075448540 @default.
• W2020267524 hasAuthorship W2020267524A5080052175 @default.
• W2020267524 hasBestOaLocation W20202675242 @default.
• W2020267524 hasConcept C126322002 @default.
• W2020267524 hasConcept C142724271 @default.
• W2020267524 hasConcept C156957248 @default.
• W2020267524 hasConcept C168563851 @default.
• W2020267524 hasConcept C170493617 @default.
• W2020267524 hasConcept C197934379 @default.
• W2020267524 hasConcept C204787440 @default.
• W2020267524 hasConcept C205679159 @default.
• W2020267524 hasConcept C27081682 @default.
• W2020267524 hasConcept C2775842315 @default.
• W2020267524 hasConcept C2777389121 @default.
• W2020267524 hasConcept C2778949969 @default.
• W2020267524 hasConcept C2780580376 @default.
• W2020267524 hasConcept C2781063702 @default.
• W2020267524 hasConcept C2781072394 @default.
• W2020267524 hasConcept C42219234 @default.
• W2020267524 hasConcept C44249647 @default.
• W2020267524 hasConcept C71924100 @default.
• W2020267524 hasConcept C98274493 @default.
• W2020267524 hasConceptScore W2020267524C126322002 @default.
• W2020267524 hasConceptScore W2020267524C142724271 @default.
• W2020267524 hasConceptScore W2020267524C156957248 @default.
• W2020267524 hasConceptScore W2020267524C168563851 @default.
• W2020267524 hasConceptScore W2020267524C170493617 @default.
• W2020267524 hasConceptScore W2020267524C197934379 @default.
• W2020267524 hasConceptScore W2020267524C204787440 @default.
• W2020267524 hasConceptScore W2020267524C205679159 @default.
• W2020267524 hasConceptScore W2020267524C27081682 @default.
• W2020267524 hasConceptScore W2020267524C2775842315 @default.
• W2020267524 hasConceptScore W2020267524C2777389121 @default.
• W2020267524 hasConceptScore W2020267524C2778949969 @default.
• W2020267524 hasConceptScore W2020267524C2780580376 @default.
• W2020267524 hasConceptScore W2020267524C2781063702 @default.
• W2020267524 hasConceptScore W2020267524C2781072394 @default.
• W2020267524 hasConceptScore W2020267524C42219234 @default.
• W2020267524 hasConceptScore W2020267524C44249647 @default.
• W2020267524 hasConceptScore W2020267524C71924100 @default.
• W2020267524 hasConceptScore W2020267524C98274493 @default.
• W2020267524 hasIssue "5" @default.

• next